Oxidative Stress and Low-Grade Inflammation in Polycystic Ovary Syndrome: Controversies and New Insights
- PMID: 33562271
- PMCID: PMC7915804
- DOI: 10.3390/ijms22041667
Oxidative Stress and Low-Grade Inflammation in Polycystic Ovary Syndrome: Controversies and New Insights
Abstract
The pathophysiology of Polycystic Ovary Syndrome (PCOS) is quite complex and different mechanisms could contribute to hyperandrogenism and anovulation, which are the main features of the syndrome. Obesity and insulin-resistance are claimed as the principal factors contributing to the clinical presentation; in normal weight PCOS either, increased visceral adipose tissue has been described. However, their role is still debated, as debated are the biochemical markers linked to obesity per se. Oxidative stress (OS) and low-grade inflammation (LGI) have recently been a matter of researcher attention; they can influence each other in a reciprocal vicious cycle. In this review, we summarize the main mechanism of radical generation and the link with LGI. Furthermore, we discuss papers in favor or against the role of obesity as the first pathogenetic factor, and show how OS itself, on the contrary, can induce obesity and insulin resistance; in particular, the role of GH-IGF-1 axis is highlighted. Finally, the possible consequences on vitamin D synthesis and activation on the immune system are briefly discussed. This review intends to underline the key role of oxidative stress and low-grade inflammation in the physiopathology of PCOS, they can cause or worsen obesity, insulin-resistance, vitamin D deficiency, and immune dyscrasia, suggesting an inverse interaction to what is usually considered.
Keywords: antioxidants; hyperandrogenism; insulin-resistance; obesity.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
The Emerging Role of Chronic Low-Grade Inflammation in the Pathophysiology of Polycystic Ovary Syndrome.Semin Reprod Med. 2015 Jul;33(4):257-69. doi: 10.1055/s-0035-1556568. Epub 2015 Jul 1. Semin Reprod Med. 2015. PMID: 26132930 Review.
-
OXIDATIVE STRESS AND REPRODUCTIVE FUNCTION: Oxidative stress in polycystic ovary syndrome.Reproduction. 2022 Nov 22;164(6):F145-F154. doi: 10.1530/REP-22-0152. Print 2022 Dec 1. Reproduction. 2022. PMID: 36279177 Review.
-
Source and amount of carbohydrate in the diet and inflammation in women with polycystic ovary syndrome.Nutr Res Rev. 2018 Dec;31(2):291-301. doi: 10.1017/S0954422418000136. Epub 2018 Jul 23. Nutr Res Rev. 2018. PMID: 30033891 Review.
-
Evaluation of antioxidant defense markers in relation to hormonal and insulin parameters in women with polycystic ovary syndrome (PCOS): A case-control study.Diabetes Metab Syndr. 2019 May-Jun;13(3):1957-1961. doi: 10.1016/j.dsx.2019.04.032. Epub 2019 Apr 23. Diabetes Metab Syndr. 2019. PMID: 31235121
-
Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy.J Steroid Biochem Mol Biol. 2018 Sep;182:27-36. doi: 10.1016/j.jsbmb.2018.04.008. Epub 2018 Apr 17. J Steroid Biochem Mol Biol. 2018. PMID: 29678491 Review.
Cited by
-
A Randomized Trial of the Efficacy of Three Weight Loss Diet Interventions in Overweight/Obese with Polycystic Ovary Syndrome.Endocr Metab Immune Disord Drug Targets. 2024;24(14):1686-1697. doi: 10.2174/0118715303286777240223074922. Endocr Metab Immune Disord Drug Targets. 2024. PMID: 38988067 Clinical Trial.
-
Antioxidant therapy for infertile couples: a comprehensive review of the current status and consideration of future prospects.Front Endocrinol (Lausanne). 2025 Jan 9;15:1503905. doi: 10.3389/fendo.2024.1503905. eCollection 2024. Front Endocrinol (Lausanne). 2025. PMID: 39850484 Free PMC article. Review.
-
Oxidative Stress in Metabolic and Endocrine Diseases: Basic and Translational Aspects.Int J Mol Sci. 2022 Apr 14;23(8):4346. doi: 10.3390/ijms23084346. Int J Mol Sci. 2022. PMID: 35457165 Free PMC article.
-
Tannic acid alleviates 3-nitropropionic acid-induced ovarian damage in Brandt's vole (Lasiopodomys brandtii).Reprod Sci. 2024 Aug;31(8):2261-2272. doi: 10.1007/s43032-024-01543-6. Epub 2024 Apr 17. Reprod Sci. 2024. PMID: 38630174
-
Effects of SGLT-2 inhibitors on clinical and biological hyperandrogenism and menstruation irregularities in patients with polycystic ovary syndrome: A systematic review of randomized trials.SAGE Open Med. 2024 Dec 19;12:20503121241308997. doi: 10.1177/20503121241308997. eCollection 2024. SAGE Open Med. 2024. PMID: 39713268 Free PMC article. Review.
References
-
- Fauser B.C.J.M. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 2004;81:19–25. - PubMed
-
- Ladrón de Guevara A., Fux-Otta C., Crisosto N., Szafryk de Mereshian P., Echiburú B., Iraci G., Perez-Bravo F., Sir-Petermann T. Metabolic profile of the different phenotypes of polycystic ovary syndrome in two Latin American populations. Fertil. Steril. 2014;101:1732–1739.e92. doi: 10.1016/j.fertnstert.2014.02.020. - DOI - PubMed
-
- Azziz R., Carmina E., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Futterweit W., Janssen O.E., Legro R.S., Norman R.J., Taylor A.E., et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: The complete task force report. Fertil. Steril. 2009;91:456–488. doi: 10.1016/j.fertnstert.2008.06.035. - DOI - PubMed
-
- Azziz R., Carmina E., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Futterweit W., Janssen O.E., Legro R.S., Norman R.J., Taylor A.E., et al. Position statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An androgen excess society guideline. J. Clin. Endocrinol. Metab. 2006;91:4237–4245. doi: 10.1210/jc.2006-0178. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical